Cytotec’s active ingredient, misoprostol, mimics protective prostaglandins and influences smooth muscle in the uterus and gastrointestinal tract. It is used in adults for prevention of NSAID-associated gastric ulcers and, under specialist supervision, for cervical ripening, labour induction, and management of early pregnancy loss.
Cytotec contains misoprostol, a synthetic analogue of prostaglandin E1. Misoprostol belongs to the prostaglandin class and has gastroprotective, uterotonic, and cervical-remodelling effects.
Cytotec contains misoprostol, a synthetic analogue of prostaglandin E1. The tablets contain 200 micrograms of misoprostol per tablet. Misoprostol belongs to the prostaglandin class and has gastroprotective, uterotonic, and cervical-remodelling effects.
Its original gastrointestinal role was to reduce the risk of ulcers associated with nonsteroidal anti-inflammatory drugs such as ibuprofen, naproxen, and diclofenac. Misoprostol increases protective mucus and bicarbonate secretion while supporting blood flow in the stomach lining. This helps the mucosa resist acid and NSAID-related injury. The Cytotec prescribing information describes this gastroprotective use [1].
Misoprostol is converted rapidly to misoprostol acid, the active metabolite responsible for most of its pharmacological effects. In the stomach, it activates prostaglandin pathways that strengthen mucosal defence. In the cervix and uterus, it promotes softening of cervical tissue and increases uterine contractions.
The same mechanism explains both its clinical usefulness and its risks. A dose that supports cervical change can also cause cramping, bleeding, diarrhoea, fever, or excessive uterine activity.
Misoprostol is converted rapidly to misoprostol acid, the active metabolite responsible for most of its pharmacological effects. In the stomach, it activates prostaglandin pathways that strengthen mucosal defence. In the cervix and uterus, it promotes softening of cervical tissue and increases uterine contractions.
Misoprostol is used in obstetric practice for cervical ripening and induction of labour. It can also be used in the management of early pregnancy loss and medical termination of pregnancy under a clinician-led protocol. Regulatory approval and clinical protocols differ by jurisdiction, including within Canadian healthcare settings.
Misoprostol is an abortifacient because it can cause uterine contractions and cervical opening that result in pregnancy expulsion. It may be used alone in some protocols or after mifepristone, which blocks progesterone activity and helps prepare the pregnancy and uterus for treatment.
For early pregnancy loss, medical management may allow the uterus to empty without an operation. The clinician confirms the pregnancy location and gestational age, assesses bleeding risk, and explains expected cramping and bleeding. Follow-up is used to confirm completion and identify continuing pregnancy, retained tissue, infection, or excessive blood loss.
Cytotec was developed primarily to reduce gastric and duodenal ulcer risk in people taking NSAIDs. NSAIDs reduce prostaglandin production, which can lower mucus and bicarbonate protection in the stomach and duodenum. Misoprostol restores prostaglandin-like activity at the mucosal surface.
The World Health Organization and NICE describe medication-based care and procedural care as established approaches, with choice guided by gestational age, medical history, patient preference, local services, and clinical assessment [2].
Several practical mistakes can lead to poor outcomes:
One overlooked detail is that fever and chills can occur after misoprostol, yet persistent high fever may also indicate infection. The timing, duration, bleeding pattern, and general condition help clinicians distinguish expected effects from complications.
Another common error is assuming that a smaller tablet strength means the medicine is suitable for self-adjustment. Tablet splitting or combining must follow the prescribed regimen, especially when uterine effects are intended.
Cytotec is NOT for you if:
Misoprostol can interact with the clinical effects of other uterotonic medicines. Combining agents that increase uterine contractions requires specialist monitoring. For gastrointestinal use, the risk-benefit assessment changes if you have inflammatory bowel disease, chronic diarrhoea, significant dehydration, or severe cardiovascular disease.
Pregnancy status must be established before Cytotec is used for ulcer prevention. A person who could become pregnant may require pregnancy assessment and contraception planning when misoprostol is prescribed for NSAID-related ulcer prevention.
Misoprostol can cause gastrointestinal and systemic effects. Abdominal pain, uterine cramping, diarrhoea, nausea, vomiting, headache, dizziness, chills, and fever are recognised reactions. Bleeding is expected in some obstetric uses, but heavy or prolonged bleeding requires urgent assessment.
Obstetric complications can include uterine tachysystole, in which contractions occur too frequently, fetal heart-rate abnormalities, retained tissue, infection, and uterine rupture. Uterine rupture is uncommon but potentially life-threatening. Risk rises with certain uterine scars, including some previous caesarean or uterine surgery histories.
The EMA’s misoprostol-related product information describes gastrointestinal reactions and pregnancy-related risks that depend on the indication and route [3].
Misoprostol, dinoprostone, and oxytocin all have roles in labour induction, but they act differently and are selected for different clinical situations. Dinoprostone is prostaglandin E2 and is available in some settings as the vaginal insert Cervidil. Oxytocin is a naturally occurring uterotonic hormone usually administered by intravenous infusion in hospital.
| Agent | Class and route | Clinical selection |
|---|---|---|
| Misoprostol | Prostaglandin E1 analogue; route varies by protocol | Cervical ripening, induction, and selected pregnancy-loss protocols |
| Dinoprostone, including Cervidil | Prostaglandin E2; commonly vaginal | Cervical ripening when a removable vaginal system is preferred |
| Oxytocin | Uterotonic hormone; intravenous infusion | Starting or strengthening contractions after cervical preparation |
Misoprostol is stable at room temperature and does not require an infusion pump, which supports its use in several clinical protocols. Dinoprostone allows clinicians to remove a vaginal insert if uterine activity becomes excessive. Oxytocin can be titrated continuously, giving the clinical team close control over contraction strength.
The choice depends on uterine scar history, gestational age, membrane status, cervical findings, fetal condition, and local policy. Misoprostol may be unsuitable after some types of uterine surgery because excessive contractions can increase the risk of uterine rupture.
In clinical practice, doctors usually frame Cytotec around the indication rather than the brand name. The same 200-microgram tablet can be relevant to very different treatment pathways, so a regimen cannot be transferred from one condition to another.
An obstetric clinician will focus on gestational age, cervical findings, uterine scar history, fetal status, bleeding risk, and access to emergency care. A gastroenterology or primary-care clinician will focus on NSAID exposure, prior ulcer history, diarrhoea risk, and whether another gastroprotective strategy is more suitable.
Consistency with the agreed regimen matters because changing the route, timing, or number of tablets can alter uterine activity or gastrointestinal tolerability. A physician may also explain that cramping and bleeding can occur during obstetric treatment, while severe pain, fainting, heavy bleeding, or persistent fever suggests a complication rather than a normal response.
Health Canada and the WHO both place misoprostol within indication-specific clinical care rather than a single universal dosing approach. Dose, frequency, route, and duration depend on the purpose of use and are agreed with a doctor or pharmacist.
Alcohol can worsen dizziness, nausea, abdominal discomfort, and dehydration, which are recognised misoprostol-related concerns in Health Canada information from 2024. Alcohol may also make it harder to judge whether weakness, faintness, or severe pain requires urgent care. During obstetric treatment, avoiding alcohol supports clearer monitoring of symptoms and recovery. During ulcer-prevention treatment, alcohol may aggravate gastrointestinal irritation even when it does not create a direct drug interaction.
The tablet should be used by the route and method prescribed for the specific indication, as reflected in European Medicines Agency product information reviewed in 2024. Splitting, crushing, or chewing can change how the tablet is administered and may make the intended dose difficult to control. This is especially relevant when buccal, sublingual, vaginal, or oral administration has been selected. Do not alter the tablet unless the prescribing clinician or pharmacist has given that exact instruction.
The effect varies. WHO guidance from 2022 describes this variation. Gastrointestinal protection is preventive and may not create a noticeable sensation. Cramping, cervical change, or bleeding can begin at different times during obstetric treatment. Lack of immediate symptoms does not justify taking additional tablets outside the agreed regimen.
Yes, diarrhoea can occur. Diarrhoea is a recognised adverse effect of misoprostol in the FDA Cytotec prescribing information from 2002. It may occur with abdominal cramping, nausea, or bloating and can be strong enough to affect treatment adherence. Seek urgent assessment for severe dehydration, fainting, blood in the stool, or diarrhoea accompanied by severe abdominal pain.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The cramps became strong after several hours and the bleeding was heavier than a period. I felt chilled that evening, then improved the next day. The follow-up appointment was reassuring because it confirmed the treatment had worked.
The first few hours were uncomfortable, with nausea and lower-abdominal cramps. I had expected the process to be quick, but bleeding continued for several days. Clear instructions about warning signs made the experience less stressful.
I took it with my anti-inflammatory medicine and noticed loose stools during the first week. The stomach discomfort I had been worried about did not return, but the diarrhoea was annoying enough that I discussed alternatives with my prescriber.
The tablets were manageable, although abdominal cramping and urgency were unpleasant at first. I did not stop them suddenly; I contacted the clinic and the treatment plan was changed after my symptoms were reviewed.
